Rheumatoid arthritis affects roughly 0.5 to 1 percent of adults worldwide, and its treatments often fall short because conventional drugs circulate through the whole body before reaching the inflamed joint. A new review published in Discover Pharmaceutical Sciences examines how hydrogel-based drug delivery systems, including hydrogel beads, microspheres, and injectable formulations, could change that picture by releasing therapeutics directly and sustainably at the site of inflammation. The review, authored by Amol Arunrao Wadhave and Ramenani Hari Babu, synthesizes recent advances in hydrogel formulations designed specifically to exploit the biochemistry of the arthritic joint.
The problem the technology addresses is well documented. Nonsteroidal anti-inflammatory drugs, glucocorticoids, disease-modifying antirheumatic drugs, and biologic agents all carry limitations: short half-lives, systemic toxicity, and poor targeting efficiency. Because rheumatoid arthritis is a chronic autoimmune disorder in which immune-driven inflammation progressively destroys joints and can complicate organs such as the lungs and heart, patients typically need long-term therapy. Hydrogels, three-dimensional hydrophilic polymer networks that absorb large quantities of water while holding their structure, offer high biocompatibility and tunable physicochemical properties that make them attractive carriers for controlled, localized, and sustained release.
The review emphasizes that the inflamed joint is not chemically neutral territory. The synovial microenvironment in rheumatoid arthritis is characteristically acidic, with pH values ranging from 6.0 to 6.8 compared with physiological pH 7.4. pH-responsive hydrogels are engineered with ionizable functional groups, such as carboxyl, amine, or sulfonic moieties, whose protonation state shifts with acidity, triggering drug release precisely where inflammation has lowered the pH. Enzyme-responsive systems take a different route into the disease process: rheumatoid arthritis pathology is marked by overexpression of matrix metalloproteinases including MMP-1, MMP-2, MMP-3, and MMP-9, along with cathepsins and elastases released from activated synoviocytes, macrophages, and infiltrating immune cells. Hydrogels built with enzyme-cleavable peptide linkers, incorporating sequences such as GPQGIWGQ, PLGLWA, or GPLGVRG, degrade only in the presence of these elevated enzymes, and some combine MMP-cleavable motifs with reactive oxygen species-sensitive or pH-responsive elements for multi-stimuli responsiveness.
Thermo-responsive and injectable hydrogels form a third major category. These systems undergo reversible sol-gel transitions at body temperature, allowing a formulation to be injected as a liquid that then gels in place, forming a depot for sustained drug release. Shear-thinning behavior permits smooth injection through a needle, followed by rapid structural recovery that secures the material within target tissue. The review notes that injectable hydrogels can fill irregular joint spaces and conform to tissue architecture, encapsulating DMARDs, biologics, and anti-inflammatory agents while responding to enzymes, pH, or temperature for on-demand release inside inflamed joints.
The range of drugs these platforms can carry is broad. NSAIDs such as ibuprofen, naproxen, and diclofenac benefit from hydrogel-mediated sustained release that maintains therapeutic concentrations at target sites while minimizing systemic toxicity. DMARDs including methotrexate, sulfasalazine, and hydroxychloroquine can achieve localized, controlled release through injectable and stimuli-responsive formulations, improving bioavailability and reducing systemic side effects. Hydrogels also serve as carriers for biologics and monoclonal antibodies, protecting sensitive biomolecules from degradation, with hybrid formulations incorporating nanoparticles or liposomes further enhancing stability and bioactivity.
Some of the most technically intricate examples combine prodrug chemistry with hydrogel reservoirs. In one described platform, a phospholipid-mimicking artemisinin prodrug was incorporated with methotrexate in drug-in-drug liposomes stabilized within an injectable hydrogel matrix, enabling sustained intra-articular release. After local administration, the released liposomes targeted synovial macrophages and fibroblasts; the prodrug remained stable outside cells but was rapidly converted to active dihydroartemisinin inside lysosomes, ensuring activation at the intended site. Another system paired hyaluronic acid microparticles with methotrexate-conjugated peptide dendrimer nanoparticles, showing pH-sensitive release in the acidic synovial environment and, in in vivo studies, reduced joint inflammation, preserved cartilage integrity, and improved bone mineral density, alongside macrophage polarization from the pro-inflammatory M1 toward the anti-inflammatory M2 phenotype. A chitosan and beta-glycerophosphate nanocomposite hydrogel encapsulating acid-responsive prodrugs of lenalidomide and hesperidin sustained pH-sensitive release and alleviated synovial inflammation and joint destruction by targeting PI3K/AKT signaling.
Light-activated systems push the concept further. Near-infrared light can trigger hydrogel degradation or activate embedded nanoparticles to release drugs or generate reactive oxygen species aimed at eliminating fibroblast-like synoviocytes, the aggressive cells that drive cartilage destruction. One photothermal-responsive methylcellulose hydrogel incorporated strontium ranelate and sodium chloride with polypyrrole-polyethylenimine nanoparticles; NIR-induced heating increased local blood flow, alleviated inflammation, and promoted cartilage repair while providing controlled drug release. A thermo-responsive hydrogel based on black phosphorus nanosheets, chitosan, and platelet-rich plasma used phototherapeutic action to target fibroblast-like synoviocytes under NIR irradiation, while the platelet-rich plasma supplied regenerative factors and chitosan provided viscoelastic support for articular cartilage. The review also describes hydrogels containing calcium peroxide as a dual oxygen and calcium ion source, sustaining singlet oxygen production to eliminate synoviocytes while released calcium ions promoted apoptosis of pathological cells and cartilage regeneration.
Beyond drug release alone, hydrogel microspheres and beads are being engineered as biomechanical and immunological tools. Superlubricating hydrogels, with friction coefficients below 0.01, emulate natural cartilage lubrication; liposome-integrated microspheres mimic boundary lubrication, and branch-crosslinked microspheres act as joint lubricants that decrease friction and wear on articular surfaces. Hyaluronic acid-based microspheres prolong drug release, while functional modifications such as methacrylated gelatin or phenylboronic acid enable targeted cell signaling and macrophage reprogramming. Polysaccharide hydrogels derived from alginate, chitosan, hyaluronic acid, or dextran add further versatility: alginate gels in the presence of divalent cations, chitosan offers mucoadhesion and pH responsiveness, and dextran enables reactive oxygen species-responsive release. By combining diffusion-controlled, swelling-controlled, and degradation-controlled release mechanisms, these materials can approach near-zero-order release kinetics for consistent therapeutic levels.
The authors are candid about the evidence gap. Most available studies remain restricted to in-vitro evaluations, with relatively few in-vivo investigations and an absence of long-term clinical data. Many reports lack comprehensive assessments of mechanical stability, biodegradation kinetics, and chronic biocompatibility, all critical for intra-articular applications, and variability in hydrogel composition, crosslinking methods, and experimental models makes direct comparisons difficult. Obstacles such as storage, degradation, sterilization, and balancing material complexity with regulatory requirements have limited clinical translation. Emerging multimodal strategies integrating gas therapy or sonodynamic therapy show promise but face challenges including precise control of gas release, potential tissue damage from excessive reactive oxygen species generation, and limited light penetration in joints.
Still, the direction of travel is clear. Hydrogel-based systems hold significant promise as innovative platforms for rheumatoid arthritis drug delivery because of their high water content, tunable properties, and capacity for localized, sustained release, and in-vitro evidence indicates they can enhance drug stability, reduce systemic side effects, and improve targeted delivery to inflamed joints. The review calls for standardized methodologies, rigorous in-vivo validation, biomimetic formulations that closely resemble the joint microenvironment, and integration of advanced drug combinations or nanocarriers. Translational work will also need to clear preclinical hurdles: appropriate animal models, GLP-compliant pivotal studies, and long-term assessments of degradation and biocompatibility. If those steps succeed, the humble water-swollen polymer bead could become a precision depot that keeps arthritis drugs working where they are needed most, and nowhere else.
Subject of Research: Hydrogel bead-based drug delivery systems for rheumatoid arthritis therapy
Article Title: Hydrogel Beads-based drug delivery systems rheumatoid arthritis
Article References: Wadhave, A. A., & Babu, R. H. (2026). Hydrogel Beads-based drug delivery systems rheumatoid arthritis. Discover Pharmaceutical Sciences, 2(1), Article 5. https://doi.org/10.1007/s44395-026-00039-3
Image Credits: AI Generated
DOI: 10.1007/s44395-026-00039-3
Keywords: rheumatoid arthritis, hydrogels, drug delivery, hydrogel beads, stimuli-responsive materials, intra-articular injection, methotrexate, NSAIDs, biologics, nanoparticles, synovial inflammation, biomaterials
News Source: Ophelia Keating. (October 30, 2026). Hydrogel Beads Could Change How Rheumatoid Arthritis Drugs Reach the Joint. Scienmag.
